Clinical Trial Update: CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating CMP-001 in combination with nivolumab for Stage IIIB/C/D melanoma with clinically apparent lymph node disease has completed. Results we…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CMP-001
• nivolumab (nivolumab)

Snippet

Sponsor: Diwakar Davar | Conditions: Melanoma, Lymph Node Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16